LadRx Corp (LADXD)

[surf1944]

8:32AM CytRx announced the presentation today of favorable results from a Phase 1b/2 clinical trial; Company is planning to submit a special protocol assessment to the FDA related to its Phase 3 pivotal trial with aldoxorubicin for patients with advanced soft tissue sarcomas (CYTR) 1.68 : Co announced the presentation today of favorable results from a Phase 1b/2 clinical trial with its tumor-targeting doxorubicin conjugate aldoxorubicin patients with advanced soft tissue sarcoma at the Connective Tissue Oncology Society 17th Annual Meeting in Prague, Czech Republic. The poster-discussion presentation was delivered by Dr. Sant Chawla, M.D., F.R.A.C.P., Director of the Sarcoma Oncology Center in Santa Monica, California. The Phase 1b/2 trial data showed clinical benefit with aldoxorubicin at the maximum tolerated dose in 10 of 13 evaluable patients with advanced soft tissue sarcomas. The data were first announced in early June 2012 at the American Society of Clinical Oncology (ASCO) conference in Chicago and also were presented at the European Society of Medical Oncology 2012 Congress in Vienna, Austria in October 2012.